A Multicenter, OBSERVational Study in PatiEnts with Geographic Atrophy Secondary to Age-related Macular Degeneration (OBSERVE)

Research summary

KRIYA-825-901(OBSERVE) is an observational study of participants with Geographic Atrophy (GA), which is an advance form of age-related macular degeneration. This is a 2-part study run in parallel to the First in Human KRIYA-825-101(VISION) open label study, designed to test how safe, tolerable and effective a gene therapy (VV-14295) is at treating GA. In part 1 of this study investigators review potential participants’ medical charts and retrospective eye examination records since 2022 to determine if they are eligible for the KRIYA-825-101 study. If participants are found not to be eligible for the VISION study, they will be enrolled onto Part 2 of the OBSERVE study. Part 2 will provide a matched control group for the VISION study. Data will be collected to compare disease progression between participants treated with gene therapy, VV-14295. Overall creating, real world data on disease progression, essential for the understanding of safety, efficacy and comparative effectiveness of gene therapies, with a view of improving future treatments for patients with GA. This study is sponsored by Kriya Therapeutics, Inc. Approximately 120 participants will be enrolled in Part 1 and 60 in Part 2 globally,

Principal Investigator

Mr Kanmin Xue

Contact us

Email: ERGO@ouh.nhs.uk

IRAS number

356315